ClinicalTrials.gg
TerminatedNCT01842633Updated Sep 1, 2017Results posted

Clinical Study to Evaluate Efficacy of New Paracetamol Formulation Compared to Ibuprofen in Headache

A Phase 3 interventional study of Paracetamol and Caffeine and Ibuprofen in Pain, sponsored by GlaxoSmithKline. Terminated at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-09-01.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
365
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 137 studies testing acetaminophen in Pain — 5 open to participants now, 5 under way, none of them phase 3. Acetaminophen · Pain.

Enrollment
13th of 137
365 · median 95
Started
2013
with 10 others
Phase 3
22 of 137
none open now
Registered
58th of 137
by date
Lead sponsor
7 of 137
GlaxoSmithKline

Among the 137 studies testing acetaminophen in Pain, this one is the 13th largest by enrollment, is one of 11 that started in 2013, is one of 22 in phase 3, and was the 58th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.

Browse Pain studies →

Open to participants now

5 of the 137 studies testing acetaminophen in Pain are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About acetaminophen

Acetaminophen: first FDA approval 1968 (NEOPAP). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 137 studies testing acetaminophen in Pain, or all of them as a file.
02

Study summary

The purpose of this multi-center study is to assess the efficacy of headache relief of new paracetamol/caffeine formulation compared to placebo and ibuprofen in episodic tension-type headache (ETTH).

03

Conditions studied

  • Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants in good general health, and with diagnosis of ETTH with following conditions:

    1. number of days with the condition is historically greater than or equal to two per month;
    2. severity of headaches is historically at least moderate;
    3. duration of headaches is historically more than or equal to 4 hours, if untreated.

Exclusion criteria

Exclusion Criteria:

  • Participant with known or suspected , allergy, intolerance or to the use of any of the study medications
  • Participant has chronic tension type headache, psychiatric disease or a significant cognitive disorder, or any chronic pain disorder.
  • Participant currently taking or has taken medications or herbal supplements within the three months that are likely to interfere with the validity of subject-rated assessments.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
365 participants (actual)

Study arms

  • Experimental
    Paracetamol/ Caffeine Caplets

    Two caplets of paracetamol/caffeine combination plus 2 placebo caplets to be administered

    Drug: Paracetamol and Caffeine

  • Active comparator
    Ibuprofen Caplets

    Two ibuprofen caplets plus two placebo caplets to be administered

    Drug: Ibuprofen

  • Placebo comparator
    Placebo Caplets

    Four placebo caplets to be administered

    Other: Placebo

Interventions

  • DrugParacetamol and Caffeine

    Drug pages: Acetaminophen · Caffeine

    Caplets containing 500 milligrams (mg) of paracetamol and 65 mg of caffeine

  • Caplets containing 200 mg of ibuprofen

  • OtherPlacebo

    Matching placebo caplets

06

What researchers measure

Primary outcomes

  1. Sum of Pain Intensity Difference (SPID) of Treatment and Placebo at 4 Hours

    SPID was calculated as the weighted sum of Pain (Headache) intensity differences at 4 hours post dose. The time-intervals used were 0-10, 10-15, 15-20, 20-25, 25-30, 30-40, 40-50, 50-60, 60-90, 90-120, 120-180, 180-240 minutes. The range of SPID at 4 hours post dose was from -12 to 4". PID was calculated as difference of pain intensity (PI) at baseline (prior to the first dose) with PI at a given time point. PI was assessed on a 4-point scale (0-no headache, 1-mild headache, 2-moderate headache, 3-severe headache).

    Time frame: Up to 4 hours post dose

Secondary outcomes

  1. Sum of Pain Intensity Difference (SPID) at 1, 2 and 3 Hours

    SPID was calculated as the weighted sum of Pain (Headache) intensity differences at 1, 2 and 3 hours post dose. The time-intervals used were 0-10, 10-15, 15-20, 20-25, 25-30, 30-40, 40-50, 50-60 minutes for SPID at 1 hour post dose. The range of SPID at 1 hour post dose was from -3 to 1. The time-intervals used were 0-10, 10-15, 15-20, 20-25, 25-30, 30-40, 40-50, 50-60, 60-90, 90-120 minutes for SPID at 2 hours post dose . The range of SPID at 2 hours post dose was from -6 to 2. The time-intervals used were 0-10, 10-15, 15-20, 20-25, 25-30, 30-40, 40-50, 50-60, 60-90, 90-120, 120-180 minutes for SPID at 3 hours post dose. The range of SPID at 3 hours post dose was from -9 to 3. PID was calculated as difference of pain intensity (PI) at baseline (prior to the first dose) with PI at a given time point. PI was assessed on a 4-point scale (0-no headache, 1-mild headache, 2-moderate headache, 3-severe headache).

    Time frame: From (Baseline) 0 to 1 hour, 0 to 2 hours, and 0 to 3 hours post dose

  2. Number of Participants With Perceptible Pain Relief

    Time frame: Baseline up to 4 hours

  3. Time to Perceptible Headache Relief

    Time to perceptible headache relief was assessed as the time when participants achieve pain relief scores (PRS) more than or equal to 1.

    Time frame: Baseline up to 4 hours

  4. Number of Participants With Meaningful Pain Relief

    Time frame: Baseline up to 4 hours

  5. Time to Meaningful Headache Relief

    Time to meaningful headache relief was assessed as time when participants reported a PRS ≥ 2.

    Time frame: Baseline up to 4 hours

  6. Total Pain Relief (TOTPAR)

    TOTPAR was calculated as the weighted sum of pain relief scores (PRS) at each time point. PRS was assessed on a 5-point scale (0-no relief, 1-a little relief, 2-some relief, 3-a lot of relief, and 4-complete relief). The range for TOTPAR for different time points were as follows: from 0 to 4 for TOTPAR at 1 hour post dose, from 0 to 8 for TOTPAR at 2 hours post dose, from 0 to 12 for TOTPAR at 3 hours post dose, and from 0 to 16 for TOTPAR at 4 hours post dose.

    Time frame: From (Baseline) 0 to 1, from 0 to 2, from 0 to 3 and from 0 to 4 hour post dose

  7. Area Under the Time-Response Curve for Change in Headache Intensity and Headache Relief (SPRID)

    SPRID was measured as sum of TOTPAR and SPID. SPID and TOTPAR were calculated as weighted sums of PID and PRS at each measurement time point, respectively. PID at each time point was calculated as difference of PI at baseline (prior to the first dose) with PI at a given time point. PI was assessed on a 4-point scale (0-no headache, 1-mild headache, 2-moderate headache, 3-severe headache). PRS was assessed on a 5-point scale (0-no relief, 1-a little relief, 2-some relief, 3-a lot of relief, and 4-complete relief). The range of SPRID for different time points were as follow: from-3 to 5 for SPRID at 1 hour post dose, from -6 to 10 for SPRID at 2 hours post dose, from -9 to 15 for SPRID at 3 hours post dose, and from -12 to 20 for SPRID at 4 hours post dose.

    Time frame: From (Baseline) 0 to 1 hour, 0 to 2 hours, 0 to 3 hours and 0 to 4 hours post dose

  8. Global Evaluation of Response to Treatment

    Global evaluation of treatment response was measured by a score in a scale from: 0-very poor, 1-poor, 2-neutral \[neither poor nor good\], 3-good, or 4-very good).

    Time frame: 4 hours

  9. Rate of Rescue Medication

    Number of participants that took rescue medication over the total number of participants for a given treatment group

    Time frame: 4 hours

  10. Change From Baseline in Headache Pain Intensity

    Change from baseline in headache pain intensity was calculated as the change (difference) from baseline PI with PI at each time-point. PI was assessed on a 4-point scale (0-no headache, 1-mild headache, 2-moderate headache, 3-severe headache).

    Time frame: At 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 180, and 240 min.

  11. Headache Relief

    The participant assessed headache relief of each treated qualifying headache at 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 180, and 240 minutes post treatment on a 5-point scale (0-no relief, 1-a little relief, 2-some relief, 3-a lot of relief, and 4-complete relief). higher headache relief score indicates better outcome.

    Time frame: At 10 min. 15 min., 20 min., 25 min., 30 min., 40 min., 50 min., 60 min., 90 min., 120 min., 180 min., 240 min.,

  12. Number of Pain Free Participants

    Number of participants with complete relief was calculated as the number of participants who reported PRS = 4-complete relief at 1 hour and 2 hours post dose.

    Time frame: 1 hour and 2 hour post dose

  13. Time to the Use of Rescue Medication.

    Time taken by the participants to use the rescue medication

    Time frame: Up to 4 hours

07

Results

Posted Jul 27, 2017
Limitations and caveats
Enrollment into the trial was terminated after randomization of 62% of the plan resulting in a significant reduction in study power. The originally planned inferential statistics (p-values) were therefore not presented in tables summarizing results.

Participant flow

Participants were recruited at clinical sites in the United States.

Participant flow — Overall Study
MilestoneParacetamol/ Caffeine CapletsIbuprofen CapletsPlacebo Caplets
Started656634
Completed626434
Not completed320
Withdrew: Screen failure100
Withdrew: Adverse event110
Withdrew: Withdrawal by subject010
Withdrew: Technical issues100

Outcome measures

PrimarySum of Pain Intensity Difference (SPID) of Treatment and Placebo at 4 Hours

SPID was calculated as the weighted sum of Pain (Headache) intensity differences at 4 hours post dose. The time-intervals used were 0-10, 10-15, 15-20, 20-25, 25-30, 30-40, 40-50, 50-60, 60-90, 90-120, 120-180, 180-240 minutes. The range of SPID at 4 hours post dose was from -12 to 4". PID was calculated as difference of pain intensity (PI) at baseline (prior to the first dose) with PI at a given time point. PI was assessed on a 4-point scale (0-no headache, 1-mild headache, 2-moderate headache, 3-severe headache).

Time frame:
Up to 4 hours post dose
Reported as:
Mean · score on a scale
Sum of Pain Intensity Difference (SPID) of Treatment and Placebo at 4 Hours
score on a scaleParacetamol/ Caffeine CapletsIbuprofen CapletsPlacebo Caplets
Sum of Pain Intensity Difference (SPID) of Treatment and Placebo at 4 Hours-6.13 ± 2.164-5.78 ± 2.098-5.86 ± 2.339
Statistical analysis
  • Paracetamol/ Caffeine Caplets vs Placebo Caplets · Treatment difference: -0.47 · 95% CI -1.36 to 0.42
SecondarySum of Pain Intensity Difference (SPID) at 1, 2 and 3 Hours

SPID was calculated as the weighted sum of Pain (Headache) intensity differences at 1, 2 and 3 hours post dose. The time-intervals used were 0-10, 10-15, 15-20, 20-25, 25-30, 30-40, 40-50, 50-60 minutes for SPID at 1 hour post dose. The range of SPID at 1 hour post dose was from -3 to 1. The time-intervals used were 0-10, 10-15, 15-20, 20-25, 25-30, 30-40, 40-50, 50-60, 60-90, 90-120 minutes for SPID at 2 hours post dose . The range of SPID at 2 hours post dose was from -6 to 2. The time-intervals used were 0-10, 10-15, 15-20, 20-25, 25-30, 30-40, 40-50, 50-60, 60-90, 90-120, 120-180 minutes for SPID at 3 hours post dose. The range of SPID at 3 hours post dose was from -9 to 3. PID was calculated as difference of pain intensity (PI) at baseline (prior to the first dose) with PI at a given time point. PI was assessed on a 4-point scale (0-no headache, 1-mild headache, 2-moderate headache, 3-severe headache).

Time frame:
From (Baseline) 0 to 1 hour, 0 to 2 hours, and 0 to 3 hours post dose
Reported as:
Mean · score on a scale
Sum of Pain Intensity Difference (SPID) at 1, 2 and 3 Hours
score on a scaleParacetamol/ Caffeine CapletsIbuprofen CapletsPlacebo Caplets
At 1 hour (n=62, 61, 33)-0.64 ± 0.488-0.56 ± 0.418-0.57 ± 0.505
At 2 hour (n=62, 61, 33)-2.21 ± 1.106-2.02 ± 1.002-2.04 ± 1.088
At 3 hour (n=61, 62, 32)-4.09 ± 1.524-3.86 ± 1.342-3.97 ± 1.528
SecondaryNumber of Participants With Perceptible Pain Relief
Time frame:
Baseline up to 4 hours
Reported as:
Number · number of participants
Number of Participants With Perceptible Pain Relief
number of participantsParacetamol/ Caffeine CapletsIbuprofen CapletsPlacebo Caplets
number of participants626133
number of censored participants010
SecondaryTime to Perceptible Headache Relief

Time to perceptible headache relief was assessed as the time when participants achieve pain relief scores (PRS) more than or equal to 1.

Time frame:
Baseline up to 4 hours
Reported as:
Median · minutes (min.)
Time to Perceptible Headache Relief
minutes (min.)Paracetamol/ Caffeine CapletsIbuprofen CapletsPlacebo Caplets
Time to Perceptible Headache Relief27.00 ± 31.27429.67 ± 41.17327.00 ± 38.042
SecondaryNumber of Participants With Meaningful Pain Relief
Time frame:
Baseline up to 4 hours
Reported as:
Number · number of participants
Number of Participants With Meaningful Pain Relief
number of participantsParacetamol/ Caffeine CapletsIbuprofen CapletsPlacebo Caplets
number of participants616032
number of censored participants121
SecondaryTime to Meaningful Headache Relief

Time to meaningful headache relief was assessed as time when participants reported a PRS ≥ 2.

Time frame:
Baseline up to 4 hours
Reported as:
Median · min.
Time to Meaningful Headache Relief
min.Paracetamol/ Caffeine CapletsIbuprofen CapletsPlacebo Caplets
Time to Meaningful Headache Relief43.33 ± 49.34254.17 ± 49.09546.67 ± 61.477
SecondaryTotal Pain Relief (TOTPAR)

TOTPAR was calculated as the weighted sum of pain relief scores (PRS) at each time point. PRS was assessed on a 5-point scale (0-no relief, 1-a little relief, 2-some relief, 3-a lot of relief, and 4-complete relief). The range for TOTPAR for different time points were as follows: from 0 to 4 for TOTPAR at 1 hour post dose, from 0 to 8 for TOTPAR at 2 hours post dose, from 0 to 12 for TOTPAR at 3 hours post dose, and from 0 to 16 for TOTPAR at 4 hours post dose.

Time frame:
From (Baseline) 0 to 1, from 0 to 2, from 0 to 3 and from 0 to 4 hour post dose
Reported as:
Mean · score on a scale
Total Pain Relief (TOTPAR)
score on a scaleParacetamol/ Caffeine CapletsIbuprofen CapletsPlacebo Caplets
Baseline-1 hour (62, 61, 33)1.31 ± 0.9221.17 ± 0.8011.14 ± 0.864
Baseline-2 hour (62, 61, 33)4.28 ± 1.8184.05 ± 1.7403.82 ± 1.886
Baseline-3 hour (61, 62, 33)7.84 ± 2.3377.51 ± 2.2507.35 ± 2.463
Baseline-4 hour (59, 59, 33)11.57 ± 3.37311.05 ± 3.77410.47 ± 4.053
SecondaryArea Under the Time-Response Curve for Change in Headache Intensity and Headache Relief (SPRID)

SPRID was measured as sum of TOTPAR and SPID. SPID and TOTPAR were calculated as weighted sums of PID and PRS at each measurement time point, respectively. PID at each time point was calculated as difference of PI at baseline (prior to the first dose) with PI at a given time point. PI was assessed on a 4-point scale (0-no headache, 1-mild headache, 2-moderate headache, 3-severe headache). PRS was assessed on a 5-point scale (0-no relief, 1-a little relief, 2-some relief, 3-a lot of relief, and 4-complete relief). The range of SPRID for different time points were as follow: from-3 to 5 for SPRID at 1 hour post dose, from -6 to 10 for SPRID at 2 hours post dose, from -9 to 15 for SPRID at 3 hours post dose, and from -12 to 20 for SPRID at 4 hours post dose.

Time frame:
From (Baseline) 0 to 1 hour, 0 to 2 hours, 0 to 3 hours and 0 to 4 hours post dose
Reported as:
Mean · score on a scale
Area Under the Time-Response Curve for Change in Headache Intensity and Headache Relief (SPRID)
score on a scaleParacetamol/ Caffeine CapletsIbuprofen CapletsPlacebo Caplets
At 1 hour (n=62, 61, 33)0.67 ± 0.5050.61 ± 0.4240.57 ± 0.473
At 2 hour (n=62, 61, 33)2.07 ± 0.9572.03 ± 0.9331.78 ± 1.116
At 3 hour (n=61, 62, 32)3.75 ± 1.2503.64 ± 1.2853.38 ± 1.581
At 4 hour (n=59, 59, 33)5.44 ± 1.8905.28 ± 2.1264.61 ± 2.613
SecondaryGlobal Evaluation of Response to Treatment

Global evaluation of treatment response was measured by a score in a scale from: 0-very poor, 1-poor, 2-neutral \[neither poor nor good\], 3-good, or 4-very good).

Time frame:
4 hours
Reported as:
Mean · score on a scale
Global Evaluation of Response to Treatment
score on a scaleParacetamol/ Caffeine CapletsIbuprofen CapletsPlacebo Caplets
Global Evaluation of Response to Treatment2.88 ± 0.7402.81 ± 0.8342.66 ± 0.946
SecondaryRate of Rescue Medication

Number of participants that took rescue medication over the total number of participants for a given treatment group

Time frame:
4 hours
Reported as:
Number · number of participants
Rate of Rescue Medication
number of participantsParacetamol/ Caffeine CapletsIbuprofen CapletsPlacebo Caplets
Rate of Rescue Medication244
SecondaryChange From Baseline in Headache Pain Intensity

Change from baseline in headache pain intensity was calculated as the change (difference) from baseline PI with PI at each time-point. PI was assessed on a 4-point scale (0-no headache, 1-mild headache, 2-moderate headache, 3-severe headache).

Time frame:
At 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 180, and 240 min.
Reported as:
Mean · score on a scale
Change From Baseline in Headache Pain Intensity
score on a scaleParacetamol/ Caffeine CapletsIbuprofen CapletsPlacebo Caplets
At 10 min.-0.03 ± 0.166-0.01 ± 0.064-0.04 ± 0.211
At 15 min.-0.10 ± 0.322-0.06 ± 0.208-0.10 ± 0.366
At 20 min.-0.27 ± 0.439-0.21 ± 0.359-0.21 ± 0.464
At 25 min.-0.45 ± 0.501-0.34 ± 0.438-0.36 ± 0.582
At 30 min.-0.66 ± 0.625-0.51 ± 0.531-0.55 ± 0.697
At 40 min.-0.92 ± 0.727-0.75 ± 0.618-0.75 ± 0.729
At 50 min.-1.07 ± 0.769-0.93 ± 0.736-0.96 ± 0.725
At 60 min.-1.26 ± 0.831-1.17 ± 0.751-1.14 ± 0.706
At 90 min.-1.51 ± 0.748-1.48 ± 0.708-1.39 ± 0.733
At 120 min.-1.76 ± 0.704-1.73 ± 0.727-1.69 ± 0.725
At 180 min.-1.95 ± 0.529-1.90 ± 0.530-1.93 ± 0.561
At 240 min.-2.01 ± 0.575-1.91 ± 0.609-1.95 ± 0.591
SecondaryHeadache Relief

The participant assessed headache relief of each treated qualifying headache at 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 180, and 240 minutes post treatment on a 5-point scale (0-no relief, 1-a little relief, 2-some relief, 3-a lot of relief, and 4-complete relief). higher headache relief score indicates better outcome.

Time frame:
At 10 min. 15 min., 20 min., 25 min., 30 min., 40 min., 50 min., 60 min., 90 min., 120 min., 180 min., 240 min.,
Reported as:
Mean · score on a scale
Headache Relief
score on a scaleParacetamol/ Caffiene CapletsIbuprofen CapletsPlacebo Caplets
10 min.0.07 ± 0.3010.03 ± 0.1400.11 ± 0.379
15 min.0.33 ± 0.6600.16 ± 0.3740.27 ± 0.635
20 min.0.68 ± 0.8700.49 ± 0.6700.60 ± 0.876
25 min.1.06 ± 1.0590.77 ± 0.8700.88 ± 0.986
30 min.1.37 ± 1.1581.17 ± 1.0721.22 ± 1.107
40 min.1.86 ± 1.3411.62 ± 1.1951.49 ± 1.182
50 min.2.15 ± 1.4041.91 ± 1.3561.82 ± 1.218
60 min.2.42 ± 1.3802.34 ± 1.2552.14 ± 1.213
90 min.2.85 ± 1.2492.91 ± 1.1622.68 ± 1.196
120 min.3.35 ± 0.9623.37 ± 1.1133.03 ± 1.206
180 min.3.69 ± 0.7493.59 ± 0.9073.44 ± 0.978
240 min.3.72 ± 0.7953.55 ± 1.1383.32 ± 1.155
SecondaryNumber of Pain Free Participants

Number of participants with complete relief was calculated as the number of participants who reported PRS = 4-complete relief at 1 hour and 2 hours post dose.

Time frame:
1 hour and 2 hour post dose
Reported as:
Number · number of participants
Number of Pain Free Participants
number of participantsParacetamol/Caffeine CapletsIbuprofen CapletsPlacebo Caplets
At 1 hour18176
At 2 hour384120
SecondaryTime to the Use of Rescue Medication.

Time taken by the participants to use the rescue medication

Time frame:
Up to 4 hours
Reported as:
Mean · Minutes
Time to the Use of Rescue Medication.
MinutesParacetamol/ Caffeine CapletsIbuprofen CapletsPlacebo Caplets
Time to the Use of Rescue Medication.239.00 ± 6.86235.14 ± 24.06235.55 ± 12.8

Adverse events

Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Paracetamol/ Caffeine Caplets—0/62 (0%)4/62 (6.5%)
Ibuprofen Caplets—0/62 (0%)3/62 (4.8%)
Placebo Caplets—0/33 (0%)1/33 (3%)
Most frequent other events
Showing 10 of 11
Most frequent other events
EventParacetamol/ Caffeine CapletsIbuprofen CapletsPlacebo Caplets
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations0/620/621/33
DyspepsiaGastrointestinal disorders1/620/620/33
NasopharyngitisInfections and infestations1/620/620/33
VIRAL UPPER RESPIRATORY TRACT INFECTIONInfections and infestations1/620/620/33
HYPOTHYROIDISMEndocrine disorders1/620/620/33
FEELING JITTERYGeneral disorders1/620/620/33
DEPRESSIONPsychiatric disorders0/621/620/33
INSOMNIAPsychiatric disorders0/621/620/33
OROPHARYNGEAL PAINRespiratory, thoracic and mediastinal disorders0/621/620/33
PARANASAL SINUS DISCOMFORTRespiratory, thoracic and mediastinal disorders0/621/620/33

Baseline characteristics

Demography data is available for 157 Participants only (safety Population).

Age, Continuous
Age, Continuous(Years)Paracetamol/ Caffeine CapletsIbuprofen CapletsPlacebo CapletsTotal
Mean39.9 ± 11.3938.1 ± 13.1338.5 ± 12.6538.9 ± 12.32
Sex: Female, Male
Sex: Female, Male(Participants)Paracetamol/ Caffeine CapletsIbuprofen CapletsPlacebo CapletsTotal
Female464423113
Male16181044
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Paracetamol/ Caffeine CapletsIbuprofen CapletsPlacebo CapletsTotal
American Indian or Alaska Native0000
Asian1012
Native Hawaiian or Other Pacific Islander0000
Black or African American46414
White565528139
More than one race1102
Unknown or Not Reported0000
08

Study locations

1 site
  • PAREXEL International, LLC
    Waltham, Massachusetts 02451, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2013 to primary completion in Mar 2015, 23 months.

Results were first posted in Jul 2017, 2 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2013
First posted
Apr 29, 2013
StartActual
Apr 1, 2013
Primary completionActual
Mar 31, 2015
CompletionActual
Mar 31, 2015
Results first posted
Jul 27, 2017
Last update
Sep 1, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01842633
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Apr 29, 2013
Start date
Apr 1, 2013
Primary completion
Mar 31, 2015
Completion
Mar 31, 2015
Results posted
Jul 27, 2017
Last update
Sep 1, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Acetaminophen · Caffeine

Start the discussion